Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 1,210,000 shares, a growth of 35.2% from the April 15th total of 895,100 shares. Currently, 5.9% of the company’s shares are short sold. Based on an average daily trading volume, of 387,900 shares, the days-to-cover ratio is currently 3.1 days.
Shares of Silverback Therapeutics stock opened at $2.96 on Monday. The company’s 50 day moving average is $3.42 and its 200 day moving average is $5.09. Silverback Therapeutics has a twelve month low of $2.80 and a twelve month high of $35.63.
A number of equities research analysts have weighed in on the stock. Jonestrading cut shares of Silverback Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, April 1st. SVB Leerink cut shares of Silverback Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, April 1st. Stifel Nicolaus cut their price objective on shares of Silverback Therapeutics from $6.00 to $5.00 in a report on Friday. The Goldman Sachs Group downgraded shares of Silverback Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, April 1st. Finally, HC Wainwright downgraded shares of Silverback Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, April 1st. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $27.15.
About Silverback Therapeutics (Get Rating)
Silverback Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers.
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- F5 Inc Is a Troubled Stock With Upside Potential
- CarMax Stock is Poised to Bounce
- Why Investors Suddenly Love These 2 Software Stocks
- Cloudflare Inc: Struggling but With Great Opportunities
- Volatile Times Are When AbbVie Shines the Brightest
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.